BRIEF-Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia

Design Therapeutics, Inc.

Design Therapeutics, Inc.

DSGN

0.00

May 18 (Reuters) - Design Therapeutics Inc DSGN.O:

  • DESIGN THERAPEUTICS ANNOUNCES FOUR-WEEK IV DATA FROM THE RESTORE-FA TRIAL OF DT-216P2 DEMONSTRATING CLINICAL IMPROVEMENTS AND COMPREHENSIVE BIOMARKER ACTIVITY IN FRIEDREICH ATAXIA

  • DESIGN THERAPEUTICS INC - DT-216P2 GENERALLY WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED

  • DESIGN THERAPEUTICS INC - DT-216P2 IMPROVES PATIENT-REPORTED FATIGUE BY OVER FIVE POINTS AFTER FOUR WEEKS

  • DESIGN THERAPEUTICS INC - TO PURSUE REGISTRATIONAL DEVELOPMENT FOR DT-216P2, UPDATE IN Q4 2026

  • DESIGN THERAPEUTICS INC - DT-216P2 AT 1 MPK IMPROVES M-FARS BY 6.4 POINTS AND UPRIGHT STABILITY BY 2.7 POINTS

Source text: ID:nGNX341dL2

Further company coverage: DSGN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.